Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for cetuximab (compound)


PubChem Substance
Name: cetuximab
PubChem Substance ID: 17397595
Synonyms:
Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (genetical recombination) (JAN); D03455; Cetuximab (USAN); Cetuximab; 205923-56-4; Erbitux
DrugBank
Identification
Name: cetuximab
Name (isomeric): DB00002
Drug Type: biotech
Synonyms:
IMC-C225; Anti EGFR
Brand: Erbitux
Category: Antineoplastic Agents
CAS number: 205923-56-4
Pharmacology
Indication: For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.
Pharmacology:
Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor...
show more »
Mechanism of Action: Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.
Half Life: 114 hrs
Toxicity: Single doses of cetuximab higher than 500 mg/m2 have not been tested. There is no experience with overdosage in human clinical trials.
Affected organisms: Humans and other mammals

Targets